RxDoctor Payments Data

George Smith, MD

Family Medicine · Pensacola, FLNPI 1861405862

Payments from drug & device makers

$2,694in general payments, 2019–2025

Across 135 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$506
  • Dexcom, Inc.$389
  • Novo Nordisk$352
  • Pfizer$267
  • Novartis$228
  • GSK$204
  • plus $748 from 15 others

What the payments were for

  • Food & beverage$2,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,694 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,781
Medicare patients
134
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol103$116,449
OzempicSemaglutide70$87,288
EliquisApixaban58$79,340
TrulicityDulaglutide54$59,405
JanuviaSitagliptin Phosphate45$46,807
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$44,657
VraylarCariprazine Hcl16$39,580
MounjaroTirzepatide33$37,667
GlyxambiEmpagliflozin/Linagliptin24$31,248
LinzessLinaclotide19$27,237
XareltoRivaroxaban26$26,334
EntrestoSacubitril/Valsartan26$25,540
JardianceEmpagliflozin22$23,436
Breo ElliptaFluticasone/Vilanterol37$16,402
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$15,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$76$120,427119 claims
Lilly USA, LLCTrulicity, Mounjaro$80$97,07387 claims
Novo NordiskOzempic$352$87,28870 claims
PfizerEliquis$267$79,34058 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$204$76,710116 claims
AbbVieVraylar, Linzess$506$66,81735 claims
Boehringer IngelheimGlyxambi, Jardiance$35$54,68446 claims
NovartisEntresto$228$25,54026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →